Global Blood Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
Global Blood Therapeutics Prices A $150.0 Million Common Stock Public Offering
Article By: NASDAQ GlobeNewswire Friday, December 7, 2018 10:25 AM EDT
Global Blood Therapeutics, Inc. today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $150.0 million.
In this article: GBT
Read
3 Top-Rated Stocks Trading At Steep Discounts
Article By: TipRanks Sunday, June 24, 2018 5:18 AM EDT
With the market so volatile right now, there are plenty of savvy opportunities to be found. The key is to look for strong stocks that have been unfairly discounted by the market. Here are our three top picks.
In this article: MU, ALRM, GBT
Read
Global Blood Therapeutics Announces Full Exercise Of Underwriter’s Option To Purchase Additional Shares
Article By: NASDAQ GlobeNewswire Monday, March 12, 2018 12:45 PM EDT
Global Blood Therapeutics, Inc. today announced that the underwriter of its previously announced underwritten public offering has exercised in full its option to purchase an additional 600,000 shares of GBT’s common stock.
In this article: GBT
Read
Global Blood Therapeutics Announces Proposed Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Thursday, March 8, 2018 5:40 PM EDT
Global Blood Therapeutics, Inc. today announced a registered offering of 3,500,000 shares of its common stock.
In this article: GBT
Read
Global Blood Therapeutics Prices A $100.0 Million Common Stock Public Offering
Article By: NASDAQ GlobeNewswire Friday, December 15, 2017 9:49 AM EDT
Global Blood Therapeutics, Inc. today announced the pricing of its underwritten public offering of its common stock for gross proceeds of approximately $100.0 million.
In this article: GBT
Read
10 Stocks To Soar In 2018
Article By: TipRanks Wednesday, December 13, 2017 2:18 PM EDT
The market is currently trading at record highs, boosted by the prospect of business-friendly tax reforms.
In this article: HRTX, LRCX, MSFT, AVGO, GBT
Read
Week In Review: China Pharma Cross-Border Deals
Article By: ChinaBio® Today Saturday, January 16, 2016 12:50 PM EDT
BioAtla LLC, a San Diego-Beijing biotech, raised $45 million from the Global BIO Impact Fund, a US bioscience investor. BioAtla will use the capital to develop its portfolio of Conditionally Active Biologic antibody therapeutics.
In this article: AGN, MDT, PFE, GBT
Read
1 to 7 of 7 Posts